Trials / Completed
CompletedNCT03732339
CTC in Predicting Neoadjuvant Chemotherapy Among LABC Patients: a Single-center, Prospective, Exploratory Clinical Trial
Predictive Value of Circulating Tumor Cells in Neoadjuvant Chemotherapy Among Locally Advanced Breast Cancer Patients: a Single-center, Prospective, Exploratory Clinical Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. The purpose of this clinical trial is to evaluate the predictive value of CTC in neoadjuvant chemotherapy among locally advanced breast cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | GILUPI CellCollector® | Use of GILUPI CellCollector® to detect CTC |
Timeline
- Start date
- 2018-08-24
- Primary completion
- 2019-03-11
- Completion
- 2019-06-30
- First posted
- 2018-11-06
- Last updated
- 2022-04-29
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03732339. Inclusion in this directory is not an endorsement.